-						
Reg. No.:						

# **Question Paper Code: UC306**

B.E./B.Tech. DEGREE EXAMINATION, APRIL / MAY 2025

#### **Professional Elective**

#### Biotechnology

#### 21BTV306- MOLECULAR THERAPEUTICS AND DIAGNOSIS

(Regulations 2021)

Duration: Three hours Maximum: 100 Marks

### **Answer All Questions**

# PART A - $(10 \times 2 = 20 \text{ Marks})$

What is the genetic basis of cystic fibrosis, and how is it inherited?
A newborn is diagnosed with phenylketonuria (PKU). How does a metabolic CO2-App enzyme deficiency contribute to this inherited disorder?

3. A patient with severe diarrhea is suspected of having a *Salmonella* infection. CO2-App How would you differentiate it from a *Shigella* infection in a clinical laboratory?

4. Name two diagnostic tests used for detecting hepatitis viruses.

CO1- U

- 5. A patient with central obesity, high blood pressure, and elevated blood glucose is CO2-App diagnosed with metabolic syndrome. Explain the possible risk factors contributing to this condition.
- 6. A patient is diagnosed with Crohn's disease and experiences abdominal pain, CO2-App weight loss, and diarrhea. How does Crohn's disease differ from ulcerative colitis in terms of affected areas and disease progression?
- 7. Describe how immunotherapy works as a targeted cancer therapy. CO1- U
- 8. Why do angiogenesis inhibitors specifically target tumor blood vessels while CO1-U sparing normal ones?
- 9. How is fluorescence in situ hybridization (FISH) used in clinical diagnostics? CO1- U
- 10. What is the working principle of flow cytometry, and what type of data does it CO1-U provide?

## $PART - B (5 \times 16 = 80 \text{ Marks})$

11. (a) Explain the process of sample collection, transport and processing for CO1- U (16) the diagnosis of diseases.

Or

- (b) What do mean by inherited disorders. Explain in detail about any 2 CO1- U (16) disorders
- 12. (a) Describe the illness effects of cholera, focusing on its impact on fluid CO3-Ana (16) balance and organ function. Discuss how real-time diagnostics can assist in timely intervention and reduce mortality rates.

Or

- (b) Discuss the challenges in diagnosing protozoan diseases in resource- CO3-Ana (16) limited settings. Propose cost-effective diagnostic strategies for diseases like amoebiosis, malaria, and Trypanosomiasis, emphasizing scalability and accuracy.
- 13. (a) Explain the mechanism of asthma, its triggers, and treatment options. CO1- U (16)
  - (b) Interpret the detail outline about the effect of the ischemic heart CO1-U (16) disease in the human system
- 14. (a) A patient with HER2-positive breast cancer is being considered for CO2-App (16) targeted therapy. Explain how monoclonal antibody therapy (e.g., trastuzumab) works in treating HER2-positive tumors.

Or

- (b) A doctor prescribes hormone therapy for an advanced case of breast CO2- App (16) cancer. Discuss the mechanism, expected benefits, and potential side effects of this treatment.
- 15. (a) Describe immunohistochemistry and explain its applications in CO2-App (16) detecting protein markers for disease diagnosis.

Or

(b) Explain the microarray approach for gene expression analysis, CO2-App (16) including its working principle, types, and applications in disease studies.